Theoretical concerns based on pharmacology include: Somatostatin-like effects -- binding sst1-5 could theoretically suppress GH release, insulin secretion, and glucagon release, though cortistatin's short half-life may limit systemic exposure Ghrelin receptor activation -- GHSR-1a activation could theoretically influence appetite and metabolism Unknown systemic effects -- the absence of any human administration data means that unexpected adverse effects cannot be excluded DSIP Side Effects# Limited human safety data from small studies: Headache -- occasionally reported Morning grogginess -- reported at higher doses, consistent with a sleep-promoting effect persisting beyond the intended sleep period Generally well-tolerated -- across the limited studies conducted, no serious adverse events have been attributed to DSIP No systematic safety characterization -- the absence of formal adverse event reporting, long-term follow-up, and immunogenicity testing means the safety profile is incompletely characterized Practical Applicability Comparison# Cortistatin# Cortistatin faces substantial practical barriers to sleep application: Route of administration -- all sleep studies used intracerebroventricular injection, which is only feasible in controlled research settings Short half-life -- rapid degradation in vivo limits duration of effect Somatostatin receptor cross-reactivity -- binding sst1-5 introduces potential metabolic and endocrine effects that complicate clinical development Research-grade only -- available only as a research peptide, not manufactured for clinical use Analog development -- structure-based analogs with improved selectivity and pharmacokinetics are being investigated but remain preclinical DSIP# DSIP is more practically accessible but still limited: Subcutaneous administration -- a clinically feasible route, unlike cortistatin's ICV requirement Available from research suppliers -- can be obtained, though quality varies between sources Very short half-life -- approximately 7-8 minutes, raising questions about whether meaningful sleep effects can be achieved given the rapid degradation No standardized protocol -- typical doses of 100-500 mcg pre-sleep are empirically derived, not established through dose-finding studies Stability concerns -- DSIP degrades in solution, adding practical challenges to preparation and storage Mechanism Specificity Comparison# This category highlights a fundamental scientific difference between the two peptides
Typical Daily Dose: 12 mg once daily (or 35 days per week)
Key Benefits Supports male and female fertility Improves sperm motility and ovulation rate Enhances fat metabolism and boosts energy levels Rich in antioxidants to fight oxidative stress Delicious orange-flavored sachets How to Use Take one sachet daily Dissolve in half a cup of water Consume 30 minutes before meals Warnings & Precautions Keep out of reach of children Not suitable for children, pregnant or breastfeeding women without medical advice Do not exceed the recommended dose Storage Conditions Store in a cool, dry place at or below 25C
IGF-1LR3 IGF-1 LR3 is a potent peptide recognized in the realm of fitness and wellness for its ability to accelerate growth and recovery
or ideally 300 minutes for clinically significant weight loss Include strength training twice weekly to preserve muscle mass and increase resting metabolic rate In fact, you can still enjoy local favourites such as chicken rice or nasi lemak just in smaller portions
